Literature DB >> 6578701

Occurrence and expression of imipemide (N-formimidoyl thienamycin) resistance in clinical isolates of coagulase-negative staphylococci.

R M Blumenthal, R Raeder, C D Takemoto, E H Freimer.   

Abstract

More than 500 clinical isolates were screened for resistance to a number of antibiotics, including imipemide (N-formimidoyl thienamycin [MK0787]). Of the 25 coagulase-negative staphylococcal isolates present in the screening sample, almost one-third showed one of two patterns of imipemide resistance. One pattern apparently involves constitutive expression of drug resistance, whereas the other pattern seems to result from an inducible resistance having an apparent induction threshold higher than the minimal inhibitory concentration of imipemide. The mechanism(s) responsible for this imipemide resistance is unclear, but may be distinct from the more common staphylococcal mechanisms of resistance to beta-lactam antibiotics. Only two of the patients from whom imipemide-resistant staphylococci were cultured had actually been treated with the antibiotic.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6578701      PMCID: PMC185105          DOI: 10.1128/AAC.24.1.61

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Plasmid-mediated penicillin beta-lactamases in Pseudomonas aeruginosa.

Authors:  Y Sawada; S Yaginuma; M Tai; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

2.  Further observations on the zone phenomenon in the bactericidal action of penicillin.

Authors:  H EAGLE
Journal:  J Bacteriol       Date:  1951-11       Impact factor: 3.490

Review 3.  How do antibiotic-producing microorganisms avoid suicide?

Authors:  A L Demain
Journal:  Ann N Y Acad Sci       Date:  1974-05-10       Impact factor: 5.691

4.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

5.  Aminoglycoside-modifying enzyme of an antibiotic-producing bacterium acts as a determinant of antibiotic resistance in Escherichia coli.

Authors:  P Courvalin; B Weisblum; J Davies
Journal:  Proc Natl Acad Sci U S A       Date:  1977-03       Impact factor: 11.205

6.  Replication and expression of plasmids from Staphylococcus aureus in Bacillus subtilis.

Authors:  S D Ehrlich
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

7.  Aminoglycoside antibiotic-inactivating enzymes in actinomycetes similar to those present in clinical isolates of antibiotic-resistant bacteria.

Authors:  R Benveniste; J Davies
Journal:  Proc Natl Acad Sci U S A       Date:  1973-08       Impact factor: 11.205

8.  In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, and Enterococcus spp.

Authors:  W K Livingston; A M Elliott; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

9.  Transduction of Methicillin Resistance in Staphylococcus aureus Dependent on an Unusual Specificity of the Recipient Strain.

Authors:  S Cohen; H M Sweeney
Journal:  J Bacteriol       Date:  1970-12       Impact factor: 3.490

10.  A new type of penicillin resistance of Staphylococcus aureus.

Authors:  L D Sabath; N Wheeler; M Laverdiere; D Blazevic; B J Wilkinson
Journal:  Lancet       Date:  1977-02-26       Impact factor: 79.321

View more
  10 in total

1.  Inducibly cefoxitin-resistant Macrococcus-like organism falsely identified as methicillin-resistant Staphylococcus aureus on CHROMagar with oxacillin.

Authors:  Joseph E Rubin; Manuel Chirino-Trejo
Journal:  J Clin Microbiol       Date:  2010-06-16       Impact factor: 5.948

2.  In vitro selection of resistance to vancomycin in bloodstream isolates of Staphylococcus haemolyticus and Staphylococcus epidermidis.

Authors:  L Herwaldt; L Boyken; M Pfaller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

3.  Imipenem/cilastatin.

Authors:  M Barza
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

Review 4.  In vitro activity of imipenem--a review.

Authors:  I Braveny
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

Review 5.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

6.  In vitro activities of enoxacin, ticarcillin plus clavulanic acid, aztreonam, piperacillin, and imipenem and comparison with commonly used antimicrobial agents.

Authors:  D Henry; A G Skidmore; J Ngui-Yen; A Smith; J A Smith
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

7.  Occurrence of a beta-lactam-inducible penicillin-binding protein in methicillin-resistant staphylococci.

Authors:  K Ubukata; N Yamashita; M Konno
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

8.  Randomized multicenter clinical trial with imipenem/cilastatin versus cefotaxime/gentamicin in the treatment of patients with non-life-threatening infections. German and Austrian Imipenem/Cilastatin Study Group.

Authors: 
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

9.  Imipenem therapy of experimental Staphylococcus epidermidis endocarditis.

Authors:  A J Berry; J L Johnston; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

10.  Interactions between glycopeptides and beta-lactams against isogenic pairs of teicoplanin-susceptible and -resistant strains of Staphylococcus haemolyticus.

Authors:  Carla Vignaroli; Francesca Biavasco; Pietro E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.